BioInvent International AB (publ)

OM:BINV Stock Report

Market Cap: kr1.7b

BioInvent International Management

Management criteria checks 3/4

BioInvent International's CEO is Martin Welschof, appointed in Sep 2018, has a tenure of 5.67 years. total yearly compensation is SEK5.06M, comprised of 54.5% salary and 45.5% bonuses, including company stock and options. directly owns 0.034% of the company’s shares, worth SEK590.23K. The average tenure of the management team and the board of directors is 4.5 years and 6.3 years respectively.

Key information

Martin Welschof

Chief executive officer

kr5.1m

Total compensation

CEO salary percentage54.5%
CEO tenure5.7yrs
CEO ownership0.03%
Management average tenure4.5yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully

Apr 09
We Think BioInvent International (STO:BINV) Needs To Drive Business Growth Carefully

Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth

Sep 01
Companies Like BioInvent International (STO:BINV) Are In A Position To Invest In Growth

Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive

Jun 02
Earnings Working Against BioInvent International AB (publ)'s (STO:BINV) Share Price Following 29% Dive

Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week

Feb 25
Analysts Are Betting On BioInvent International AB (publ) (STO:BINV) With A Big Upgrade This Week

We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely

Sep 28
We're Hopeful That BioInvent International (STO:BINV) Will Use Its Cash Wisely

Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook

Aug 31
Time To Worry? Analysts Just Downgraded Their BioInvent International AB (publ) (STO:BINV) Outlook

CEO Compensation Analysis

How has Martin Welschof's remuneration changed compared to BioInvent International's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-kr335m

Dec 31 2023n/an/a

-kr330m

Sep 30 2023n/an/a

-kr311m

Jun 30 2023n/an/a

-kr304m

Mar 31 2023n/an/a

-kr48m

Dec 31 2022kr5mkr3m

-kr43m

Sep 30 2022n/an/a

-kr43m

Jun 30 2022n/an/a

-kr42m

Mar 31 2022n/an/a

-kr266m

Dec 31 2021kr5mkr3m

-kr278m

Sep 30 2021n/an/a

-kr171m

Jun 30 2021n/an/a

-kr141m

Mar 31 2021n/an/a

-kr123m

Dec 31 2020kr5mkr3m

-kr76m

Sep 30 2020n/an/a

-kr146m

Jun 30 2020n/an/a

-kr150m

Mar 31 2020n/an/a

-kr144m

Dec 31 2019kr4mkr2m

-kr139m

Sep 30 2019n/an/a

-kr130m

Jun 30 2019n/an/a

-kr116m

Mar 31 2019n/an/a

-kr126m

Dec 31 2018kr3mkr800k

-kr123m

Compensation vs Market: Martin's total compensation ($USD466.00K) is about average for companies of similar size in the Swedish market ($USD436.42K).

Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.

CEO

Martin Welschof (62 yo)

5.7yrs

Tenure

kr5,061,000

Compensation

Dr. Martin Welschof, Ph D had been the Chief Executive Officer of Opsona Therapeutics Limited since February 2012. Dr. Welschof has been Chief Executive Officer at BioInvent Intl AB (publ) since 2018.He i...

Leadership Team

NamePositionTenureCompensationOwnership
Martin Welschof
President & CEO5.7yrskr5.06m0.034%
SEK 590.2k
Stefan Ericsson
Chief Financial Officer8.3yrsno data0.012%
SEK 210.8k
Marie Moores
Chief Operating Officer2.3yrsno datano data
Kristoffer Hansson
Senior Vice President of Technical Operations7.7yrsno data0.034%
SEK 587.6k
Björn Frendéus
Chief Scientific Officerno datakr2.35m0.035%
SEK 608.4k
Cecilia Hofvander
Senior Director of Investor Relations3.3yrsno datano data
Andres McAllister
Chief Medical Officer7.3yrsno data0.0046%
SEK 79.2k
Ingrid Teige
Head of Preclinical Researchno datano datano data
Sylvie Ryckebusch
Chief Business Officer1.9yrsno data0.035%
SEK 602.5k
Ingunn Lindvig
Senior Vice President of Regulatory Affairsless than a yearno datano data

4.5yrs

Average Tenure

58yo

Average Age

Experienced Management: BINV's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bernd Seizinger
Independent Director6.3yrskr420.00k0.10%
SEK 1.7m
Leonard Kruimer
Independent Chairman of the Board6.3yrskr682.00k0.051%
SEK 883.8k
Thomas Hecht
Independent Director3.8yrskr510.00kno data
Vincent Ossipow
Independent Director3.1yrskr475.00kno data
Alexander Rudensky
Member of Scientific Advisory Board7.3yrsno datano data
Falk Nimmerjahn
Member of Scientific Advisory Board7.3yrsno datano data
Vessela Alexieva
Employee Representative Directorno datano data0.0014%
SEK 24.6k
Erik Esveld
Director1.1yrskr475.00k0.027%
SEK 474.2k
Kristoffer Bissessar
Independent Director4yrskr520.00k0.044%
SEK 764.1k
Rienk Offringa
Member of Scientific Advisory Board7.3yrsno datano data
Mark Cragg
Member of Scientific Advisory Boardno datano datano data
Stephen Beers
Member of Scientific Advisory Boardno datano datano data

6.3yrs

Average Tenure

64yo

Average Age

Experienced Board: BINV's board of directors are considered experienced (6.3 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.